See the DrugPatentWatch profile for keytruda

Keytruda, also known as pembrolizumab, is an immunotherapy drug used to treat various types of cancer. Like all medications, Keytruda can have side effects. These side effects can be managed through a variety of methods, which we will explore below.

First, it is essential to understand the potential side effects of Keytruda. Common side effects include fatigue, rash, itching, nausea, and diarrhea [1]. More severe side effects can include immune-mediated inflammation of healthy organs, such as the lungs, colon, or liver [1].

To manage these side effects, patients should work closely with their healthcare team. The following strategies can be employed:

1. Fatigue: Patients should try to maintain a regular sleep schedule and engage in light-to-moderate physical activity, as approved by their healthcare provider [1].
2. Skin reactions: Patients should protect their skin from the sun, avoid tight-fitting clothing, and use mild soaps and lotions [1].
3. Gastrointestinal side effects: Patients should eat small, frequent meals and stay hydrated [1].
4. Immune-mediated inflammation: Patients may require corticosteroids or other immunosuppressive therapies to manage these side effects [1].

Healthcare providers should monitor patients closely for signs of side effects and adjust treatment as necessary [1]. Patients should report any new or worsening symptoms to their healthcare team immediately.

In some cases, side effects may lead to treatment discontinuation. Keytruda's patent expiration in 2028 may lead to increased access to biosimilars, potentially reducing costs and expanding treatment options for patients [2].

In summary, Keytruda's side effects can be managed through a variety of strategies, including monitoring, lifestyle modifications, and medication. Patients should work closely with their healthcare team to address any side effects that arise.

Sources:
[1] Keytruda (pembrolizumab) prescribing information. Merck Sharp & Dohme Corp. 2021. <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>
[2] Keytruda (pembrolizumab) drug patent information. DrugPatentWatch.com. 2023. <https://www.drugpatentwatch.com/drugs/keytruda>